Medexus Pharmaceuticals (MDP) AGM 2024 summary

Opening remarks and agenda

• Meeting commenced with a welcome and procedural notes, including consent for recording and privacy disclosures.

• Chair introduced the agenda and invited the CEO to provide an update on recent news regarding Treosulfan.

Strategic initiatives and plans

• FDA review of Treosulfan NDA is ongoing, with a new PDUFA goal date set for January 30, 2025.

• No new clinical data required by FDA; review extension is for further analysis of existing data.

• Preparations underway for potential Treosulfan approval and commercial launch in the US in the first half of 2025.

• Commercialization of Treosulfan expected to significantly grow revenues if approved.

Board and executive committee updates

• Seven directors nominated for election, as specified in the management information circular.

• No additional nominations received; nominations closed.